Short closure time values in PFA-100® are related to venous thrombotic risk. Results from the RETROVE Study.

[1]  M. Prins,et al.  Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism , 2017, The New England journal of medicine.

[2]  Andrew D. Johnson,et al.  Platelet function as a risk factor for venous thromboembolism in the Framingham Heart Study. , 2017, Thrombosis research.

[3]  W. Ageno,et al.  Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[4]  P. Reitsma,et al.  Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice. , 2016, Blood.

[5]  M. Schindewolf,et al.  The Role of Platelets in Venous Thromboembolism , 2016, Seminars in Thrombosis & Hemostasis.

[6]  Miquel Vázquez-Santiago,et al.  Age and gender effects on 15 platelet phenotypes in a Spanish population , 2016, Comput. Biol. Medicine.

[7]  David N. Ku,et al.  A Predictive Model of High Shear Thrombus Growth , 2016, Annals of Biomedical Engineering.

[8]  A. Franco,et al.  Platelets at the interface of thrombosis, inflammation, and cancer. , 2015, Blood.

[9]  Sara J. Israels.  Laboratory testing for platelet function disorders , 2015, International journal of laboratory hematology.

[10]  R. Abbate,et al.  Platelet function tests: a comparative review , 2015, Vascular health and risk management.

[11]  O. Tcherniantchouk,et al.  Decreased Threshold of Aggregation to Low-Dose Epinephrine is Evidence of Platelet Hyperaggregability in Patients with Thrombosis , 2014, Hematology reports.

[12]  C. Martinez,et al.  Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer , 2014, Thrombosis and Haemostasis.

[13]  S. Harding,et al.  Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser , 2013, Platelets.

[14]  D. Xavier,et al.  Low-dose aspirin for preventing recurrent venous thromboembolism. , 2012, The New England journal of medicine.

[15]  W. Ageno,et al.  Aspirin for preventing the recurrence of venous thromboembolism. , 2012, The New England journal of medicine.

[16]  A. Walch,et al.  Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo , 2012, The Journal of experimental medicine.

[17]  E. Tekgündüz,et al.  Sticky Platelet Syndrome in Patients with Uninduced Venous Thrombosis , 2011, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[18]  F. Peyvandi,et al.  Role of von Willebrand factor in the haemostasis. , 2011, Blood transfusion = Trasfusione del sangue.

[19]  I. Martinelli,et al.  Risk factors for venous and arterial thrombosis. , 2011, Blood transfusion = Trasfusione del sangue.

[20]  B. Lämmle,et al.  von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. , 2011, Blood.

[21]  P. Prandoni.  Venous and arterial thrombosis: two aspects of the same disease? , 2009, European journal of internal medicine.

[22]  A. Gori,et al.  Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. , 2009, American journal of clinical pathology.

[23]  Emmanuel J Favaloro,et al.  Clinical Utility of the PFA-100 , 2008, Seminars in thrombosis and hemostasis.

[24]  M. Furman,et al.  Indices of platelet activation and the stability of coronary artery disease , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  W. Siess,et al.  Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood , 2006, Thrombosis and Haemostasis.

[26]  J. Fontcuberta,et al.  The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism , 2005, Thrombosis and Haemostasis.

[27]  F. Rosendaal,et al.  ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden , 2005, Journal of thrombosis and haemostasis : JTH.

[28]  D. Hossfeld,et al.  Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism. , 2002, Thrombosis research.

[29]  B. Jilma.  Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. , 2001, The Journal of laboratory and clinical medicine.

[30]  R. Bertina,et al.  Elevated Factor VIII Levels and the Risk of Thrombosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[31]  E. Favaloro,et al.  Utility of the PFA‐100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  L. Almasy,et al.  Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. , 2000, American journal of human genetics.

[33]  L. Almasy,et al.  Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[34]  Brian Savage,et al.  Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor , 1996, Cell.

[35]  J. Herbert,et al.  Importance of platelets in experimental venous thrombosis in the rat. , 1992, Blood.

[36]  B. Lindblad,et al.  A prospective study of the incidence of deep‐vein thrombosis within a defined urban population , 1992, Journal of internal medicine.

[37]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[38]  J. Kruschke.  Chapter 20 – Metric Predicted Variable with Multiple Nominal Predictors , 2015 .